SCHEMBL20116037

SCHEMBL20116037

CC(C)c1noc2ccc(-c3noc(C4CCN(C(=O)OC(C)(C)C)CC4)n3)cc12

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 4/20 0.47
SMN1; SMN2 Q16637 4/20 0.46
LMNA P02545 2/20 0.46
TSHR P16473 2/20 0.46
TLR8 Q9NR97 1/20 0.45
TLR7 Q9NYK1 1/20 0.45
SMO Q99835 1/20 0.45
HDAC4 P56524 3/20 0.45
ALDH1A1 P00352 2/20 0.43
DPP4 P27487 1/20 0.42
DPP8 Q6V1X1 1/20 0.42
DPP7 Q9UHL4 1/20 0.42
EPHA2 P29317 1/20 0.42
KDR P35968 1/20 0.42
EPHB4 P54760 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22357917 0.93 GPR119 (0.47) GPR119SMN1; SMN2LMNATSHRTLR8
SCHEMBL20116613 0.90 SMO (0.53) SMN1; SMN2LMNATSHRTLR8TLR7
SCHEMBL22357932 0.88 GPR119 (0.50) GPR119SMN1; SMN2LMNATSHRSMO
SCHEMBL20117146 0.85 SMN1; SMN2 (0.55) SMN1; SMN2LMNATSHRSMOALDH1A1
SCHEMBL20117150 0.85 SMN1; SMN2 (0.48) SMN1; SMN2LMNATSHRTLR8TLR7
SCHEMBL20676350 0.84 GRM5 (0.53) SMN1; SMN2LMNATSHRALDH1A1
SCHEMBL20676490 0.83 TLR9 (0.43) SMN1; SMN2LMNATSHRTLR8TLR7
SCHEMBL22358294 0.83 GPR119 (0.50) GPR119SMOHDAC4
SCHEMBL20117119 0.81 SMN1; SMN2 (0.45) SMN1; SMN2LMNATSHRTLR8TLR7
SCHEMBL20117162 0.81 SMN1; SMN2 (0.45) GPR119SMN1; SMN2LMNATSHRSMO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-20200262828-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2020-08-20 US disclosed
WO-2019209948-A9 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. (US) 2020-01-02 WO disclosed
WO-2019018795-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2019-01-24 WO disclosed
WO-2018081167-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2018-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873298-B2 Compounds and uses thereof NLN, ACHE, CLN6 GPR119 2922/4885SMN1; SMN2 13/4885LMNA 1966/4885
US-20200262828-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 GPR119 2922/4885SMN1; SMN2 13/4885LMNA 1966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.